Table 5.

Estimated treatment effects at weeks 12, 24 and 36 in primary outcome

	Estimate of difference between SCT and Control	SE	95% CI	p Value
Intention-to-treat analysis
6MWT
Week 12	22.70	19.00	(−15.14 to 60.50)	0.23
Week 24	11.80	20.40	(−28.77 to 52.36)	0.56
Week 36	27.42	20.35	(−13.06 to 67.90)	0.18
TUG
Week 12	0.069	0.236	(−0.402 to 0.541)	0.77
Week 24	−0.132	0.250	(−0.630 to 0.365)	0.60
Week 36	−0.457	0.252	(−0.960 to 0.045)	0.08
MSWS-12
Week 12	−4.91	4.47	(−13.82 to 4.00)	0.28
Week 24	−0.59	4.69	(−9.91 to 8.73)	0.90
Week 36	0.38	4.57	(−8.71 to 9.47)	0.93
Secondary analysis
6MWT
Week 12	39.00	18.44	(2.26 to 75.73)	0.04
Week 24	27.44	19.23	(−10.82 to 65.70)	0.16
Week 36	40.03	18.97	(2.27 to 77.79)	0.04
TUG
Week 12	0.204	0.255	(−0.306 to 0.713)	0.43
Week 24	−0.020	0.261	(−0.542 to 0.502)	0.94
Week 36	−0.367	0.262	(−0.890 to 0.156)	0.17
MSWS-12
Week 12	−7.63	4.65	(−16.89 to 1.63)	0.11
Week 24	−2.50	4.78	(−12.01 to 7.02)	0.60
Week 36	−1.57	4.69	(−10.93 to 7.78)	0.74

MSWS-12, Multiple Sclerosis Walking Scale-12; 6MWT, Six-Minute Walk Test; TUG, Timed Up and Go.